CAU
GILD icon

Caxton Associates (UK)’s Gilead Sciences GILD Stock Holding History

Caxton Associates (UK)’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,441
Closed -$201K – 841
2026
Q1 		$201K Sell
1,441
-548,559
-100% -$76.8M ﹤0.01% 725
2025
Q4 		$67.5M Buy
+550,000
New +$66.8M 1.32% 14
2025
Q2 		– Sell
-5,013
Closed -$562K – 770
2025
Q1 		$562K Buy
+5,013
New +$517K 0.02% 451

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Caxton Associates (UK)'s GILD Position: Q2 2026 in Review

Caxton Associates (UK) sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 1,441 shares — an estimated $201K sold.

Caxton Associates (UK) first reported a position in GILD in Q1 2025 and held it in 3 quarters. The position peaked at $67.5M in Q4 2025. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Caxton Associates (UK) reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
  • Caxton Associates (UK) sold 1,441 Gilead Sciences shares in Q2 2026, an estimated $201K.
  • Caxton Associates (UK) first reported a position in Gilead Sciences in Q1 2025 and held it in 3 quarters.
  • Caxton Associates (UK)'s Gilead Sciences position peaked at $67.5M in Q4 2025.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.